Harbour BioMed gets FDA approval for Phase II NPC trial

FDG-PET/CT scan of a patient with nasopharyngeal cancer. Transverse slice demonstrating FDG-positive primary site. Credit: Gulec SA et al.



  • Harbour BioMed